Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a trial that included androgen-independent prostate cancer patients, 2 drug regimens were shown by randomized phase II analysis to be comparable. Both produced survival advantage when compared to prior series, including those in which mitoxantrone and prednisone were used.

Chemotherapy Offers Survival Benefit in Androgen-Independent Prostate Cancer